Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
- PMID: 33716105
- DOI: 10.1016/j.annonc.2021.02.014
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
Conflict of interest statement
Disclosure AV reports invited speaker roles for Roche, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, EISAI, IPSEN, INCYTE, Pierre Fabre, Delcath, Lilly and Advisory Boards for Roche, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, EISAI, IPSEN, INCYTE, Pierre Fabre, BTG, Lilly, AstraZeneca and Merck. EM has received honoraria for lecture and advisory boards from Roche, Amgen, Servier, Astra Zeneca, Bayer, Merck-Serono, Pierre Fabre and Sanofi, and grant support from AIRC and speaker support from ESMO.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical